The purpose of the present study was to assess the effect of GLP-1, administered in combination with the thiazolidinedione, pioglitazone, on glucose, insulin, glucagon, free fatty acids (FFAs ...

Recently, the US FDA approved initial combination therapy ... responsible for up to 70% of the insulin response after oral glucose in healthy subjects. GLP-1 and GIP are rapidly degraded by ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists ... once their cells stop responding to insulin, the hormone that controls blood glucose.

today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in ...

It is a GLP-1 receptor agonist and stimulates insulin release in the presence of elevated blood glucose,” Nirosen Vijiaratnam, MD, from the department of clinical and movement neurosciences ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.